.jpeg)
.png)
About NCG
Novadigm Consulting group provides a broad range of management consulting services in most areas of biopharmaceuticals, diagnostics and biotechnology. These are provided either by a single consultant, small teams or by large teams sourced from a network of consultants. These services are provided by experienced consultants and executives. NCG is also affiliated with the Umbrex community of over 600 senior independent management consultants with backgrounds from Tier 1 management consulting firms. Novadigm can therefore assemble teams that have deep expertise in almost all areas of biopharma, diagnostics and biotechnology.
Services NCG can provide expertise in for example:
- Technology and innovation management
- Drug discovery, pre-clinical and clinical development
- Biologics manufacturing and analytics
- Diagnostic
- Business and corporate development
- Pipeline and market assessment
- Portfolio planning and decision theory
- Drug development and therapeutic area strategies
- Drug launch planning
- Venture capital and public financing
- Interim executive services
.jpeg)
Team
Per Lindell, Sc.D., M.Sc.
Dr Lindell has a Doctor of Science in Biochemical Engineering from Massachusetts Institute of Technology, and a Master of Science in Chemical Engineering from the Royal Institute of Technology in Stockholm.
At Pharmacia and several biotechnology companies he has managed drug discovery, development and manufacturing. At BASF Pharma he was Head of strategic planning and also managed several large product launch and business development projects. At Boston Consulting Group and Arthur D. Little he was a management consultant and engagement manager, involved in numerous strategy, M&A and post-merger integration projects. At IBM Global Services he was a leader in the Pharma Strategy Group. He has managed numerous projects for biotechnology companies in a range of therapeutic areas as well as biologics manufacturing, both as an employee and a management consultant.
Dr. Lindell has experience from most therapeutic modalities, including gene therapy (extensive experience with AAV vectors), gene silencing (siRNA, shRNA, ddRNAi, antisense), small molecules, proteins including antibodies, and peptides. His therapeutic area experience includes oncology (solid and liquid tumors), gastrointestinal (functional and IBD), infectious disease (including HCV and HBV), CNS & pain, ophthalmology, immunology including allergy & RA, cardiovascular and respiratory .
At Pharmacia and several biotechnology companies he has managed drug discovery, development and manufacturing. At BASF Pharma he was Head of strategic planning and also managed several large product launch and business development projects. At Boston Consulting Group and Arthur D. Little he was a management consultant and engagement manager, involved in numerous strategy, M&A and post-merger integration projects. At IBM Global Services he was a leader in the Pharma Strategy Group. He has managed numerous projects for biotechnology companies in a range of therapeutic areas as well as biologics manufacturing, both as an employee and a management consultant.
Dr. Lindell has experience from most therapeutic modalities, including gene therapy (extensive experience with AAV vectors), gene silencing (siRNA, shRNA, ddRNAi, antisense), small molecules, proteins including antibodies, and peptides. His therapeutic area experience includes oncology (solid and liquid tumors), gastrointestinal (functional and IBD), infectious disease (including HCV and HBV), CNS & pain, ophthalmology, immunology including allergy & RA, cardiovascular and respiratory .